🟢 Iovance Biotherapeutics is trading 9.5% up today as biotech stocks rally on Moderna results

Iovance Biotherapeutics is trading 9.5% up at $7.70, reversing the unexplained 4.6% pre-market decline reported before the August 19, 2026 open, amid a biotech-sector rally following Moderna’s positive Phase 3 personalized cancer-vaccine results with Merck.

• The XBI biotech ETF rose 3.73%, providing the strongest available explanation.
• No new company-specific announcement or filing was identified.
• August 6 earnings remain supportive background, but are not a new catalyst.